1. health and fitness

Chronic Myelocytic Leukemia (CML, Chronic Myeloid
Leukemia) Market Symptoms, Analysis and Outlook, Overview
and Pipeline Review, H1 2016
Summary
Global Markets Direct's, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1
2016', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline
landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic
Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research and development history and latest
news and press releases. Additionally, the report provides an overview of key players involved in therapeutic
development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and features dormant and
discontinued projects.
For More Information, Visit @ http://www.radiantinsights.com/research/chronic-myelocytic-leukemia-cmlchronic-myeloid-leukemia-pipeline-review-h1-2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML,
Chronic Myeloid Leukemia)
- The report reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) by
companies and universities/research institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
therapeutics and enlists all their major and minor projects
- The report assesses Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) therapeutics based on drug
target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic
Myeloid Leukemia)
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic
Leukemia (CML, Chronic Myeloid Leukemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic
Myeloid Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove
them from pipeline
Request Sample Copy of This Report @ http://www.radiantinsights.com/research/chronic-myelocytic-leukemiacml-chronic-myeloid-leukemia-pipeline-review-h1-2016/request-sample
Table of Contents
Table of Contents 2
Introduction 6
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 7
Therapeutics Development 8
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies
10
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by
Universities/Institutes 15
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 17
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 21
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by
Universities/Institutes 26
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics
Development 28
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 82
Drug Profiles 99
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates 293
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 440
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 446
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 448
Appendix 457
For More Information, Visit @ http://www.radiantinsights.com/research/chronic-myelocytic-leukemia-cmlchronic-myeloid-leukemia-pipeline-review-h1-2016
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research
solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: [email protected]
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com